News | October 30, 2025
Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
The event will be attended by 35,000+ industry professionals
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Subscribe To Our Newsletter & Stay Updated
